Cargando…

Efficacy of Topiramate Alone and Topiramate Plus Vitamin D3 in the Prophylaxis of Pediatric Migraine: A Randomized Clinical Trial

OBJECTIVE: Topiramate is effective in the prevention of pediatric migraine, and studies show that vitamin D(3) supplementation might also be useful in the treatment of adult migraineurs with a normal vitamin D(3) level. The present study aimed at comparing the efficacy and safety of topiramate plus...

Descripción completa

Detalles Bibliográficos
Autores principales: FALLAH, Razieh, SARRAF YAZD, Saeedreza, SOHREVARDI, Seid Mojtaba
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Shahid Beheshti University of Medical Sciences 2020
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7660031/
https://www.ncbi.nlm.nih.gov/pubmed/33193786
Descripción
Sumario:OBJECTIVE: Topiramate is effective in the prevention of pediatric migraine, and studies show that vitamin D(3) supplementation might also be useful in the treatment of adult migraineurs with a normal vitamin D(3) level. The present study aimed at comparing the efficacy and safety of topiramate plus vitamin D(3) and topiramate alone in the prophylaxis of pediatric migraine. MATERIALS & METHODS: In a single-blinded, randomized, clinical trial, 5-15-year-old children with migraine headaches, referred to the Pediatric Neurology Clinic of Shahid Sadoughi Medical Sciences University, Yazd, Iran from January 2016 to January 2017, were randomly allocated to receive 2 mg/kg/day of topiramate or 2 mg/kg/day of topiramate plus one 500,000 IU vitamin D(3 )pearl weekly for two consecutive months. Primary outcomes were the reduction of monthly frequency, severity, duration, and the disability score of migraine, and the secondary outcomes included a good response to treatment (more than 50% reduction in monthly headache frequency) and a lack of clinical adverse events. RESULTS: Totally, 31 female and 26 male children with the mean age of 10.02±2.11 years were evaluated. Both drugs were effective in the reduction of monthly frequency, severity, duration, and disability for headaches. Nevertheless, the combination of topiramate and vitamin D(3) was more effective than topiramate alone in reducing the monthly headaches frequency (6.12±1.26 vs. 9.87±2.44 times, P=0.01) and disability score (19.24±6.32 vs. 22.11±7.91, P=0.02). Good response to treatment was observed in 60.7% and 75.9% of the subjects in the topiramate alone and topiramate plus vitamin D(3) groups, respectively, and topiramate plus vitaminD3 was more effective (P= 0.01). Transient mild side effects were observed in 14.3% and 17.2% of the subjects in the topiramate alone and topiramate plus vitamin D(3) groups, respectively (P=0.8). CONCLUSION: A combination of topiramate and vitamin D(3) might be considered safe and more effective than topiramate alone in the prophylaxis of pediatric migraine.